```html

Ineffective Erythropoiesis (Anemia of Chronic Disease)

Overview

Anemia of chronic disease (ACD), also called anemia of inflammation or anemia of chronic illness, is a type of ineffective erythropoiesis in which the bone marrow’s ability to produce healthy red blood cells (RBCs) is impaired by ongoing inflammation, infection, or malignancy. Unlike iron‑deficiency anemia, the body usually has adequate iron stores, but the iron is “locked away” and unusable for hemoglobin synthesis.

Who it affects: ACD can occur at any age but is most common in adults over 50 years old and in individuals with chronic conditions such as rheumatoid arthritis, chronic kidney disease (CKD), inflammatory bowel disease, HIV, or solid‑organ cancers.

Prevalence: Approximately 5‑10 % of the U.S. adult population has some form of anemia, and ACD accounts for up to 30 % of these cases, especially in hospitalized or long‑term care settings. Worldwide, ACD is the second most common cause of anemia after iron‑deficiency anemia (WHO, 2021).

Symptoms

Symptoms arise from reduced oxygen delivery to tissues and can range from mild to severe.

• Fatigue and weakness – the most universal complaint; patients often feel “tired after a short walk.”
• Pallor – noticeable in the skin, nail beds, and conjunctiva.
• Shortness of breath – especially on exertion; may be misattributed to the underlying disease.
• Dizziness or light‑headedness – can lead to falls in older adults.
• Rapid or irregular heartbeat (tachycardia) – the heart works harder to pump oxygen‑rich blood.
• Cold hands and feet – peripheral vasoconstriction due to low oxygen.
• Headaches – result from mild cerebral hypoxia.
• Reduced exercise tolerance – patients may stop activities they previously enjoyed.
• Chest pain – rare, but possible in patients with pre‑existing heart disease when anemia is severe.
• Impaired concentration or “brain fog” – cognitive slowing related to inadequate cerebral oxygenation.

Causes and Risk Factors

Primary Pathophysiologic Mechanisms

1. Inflammatory cytokines (IL‑6, TNF‑α, IFN‑γ) increase hepatic production of hepcidin, a hormone that blocks iron release from macrophages and intestinal absorption.
2. Reduced erythropoietin (EPO) response – the kidneys produce less EPO in CKD, and inflammation blunts the marrow’s response to any EPO that is produced.
3. Shortened RBC lifespan – cytokines promote macrophage-mediated clearance of erythrocytes.
4. Bone‑marrow suppression – chronic disease can directly inhibit progenitor cell proliferation.

Common Underlying Conditions

• Chronic kidney disease (especially stage 3–5)
• Rheumatoid arthritis and other autoimmune disorders
• Chronic infections (HIV, hepatitis B/C, tuberculosis)
• Solid tumors (lung, breast, colorectal) and hematologic malignancies
• Inflammatory bowel disease (Crohn’s, ulcerative colitis)
• Heart failure and chronic liver disease

Risk Factors

• Age > 50 years
• Long‑standing inflammatory or infectious disease
• CKD with reduced glomerular filtration rate (GFR < 60 mL/min/1.73 m²)
• Use of immunosuppressive drugs (e.g., TNF‑α inhibitors) that may mask classic inflammatory signs
• Malnutrition or vitamin B12/folate deficiency that can coexist and worsen anemia.

Diagnosis

Initial Laboratory Evaluation

Test	Typical ACD Finding
Complete blood count (CBC)	Low hemoglobin (Hb) & hematocrit, mild‑to‑moderate normocytic, normochromic anemia (MCV 80‑100 fL).
Serum iron	Decreased
Total iron‑binding capacity (TIBC)	Decreased
Ferritin	Normal or elevated (reflects stored iron)
Reticulocyte count	Low or inappropriately normal (underproduction)
Erythropoietin level	Inappropriately low for degree of anemia
CRP / ESR	Elevated, indicating underlying inflammation

Additional Studies (when indicated)

• Bone‑marrow biopsy – rarely needed; may show reduced erythroid precursors.
• Renal function panel – serum creatinine, eGFR to assess CKD‑related anemia.
• Hepcidin assay – emerging test, not yet routine, useful in research settings.
• Iron studies for differential diagnosis – to rule out concurrent iron‑deficiency anemia.

Diagnostic Criteria (per WHO)

A diagnosis of ACD is made when:

1. Hemoglobin is < 13 g/dL in men or < 12 g/dL in women,
2. Serum ferritin ≥ 100 ng/mL (or ≥ 30 ng/mL when inflammation is present),
3. Serum iron < 60 µg/dL and TIBC < 250 µg/dL, and
4. There is a chronic inflammatory, infectious, or malignant condition that can explain the anemia.

Treatment Options

Address the Underlying Disease

The cornerstone of therapy is optimal control of the chronic condition that drives inflammation.

• DMARDs (disease‑modifying antirheumatic drugs) for rheumatoid arthritis.
• Antiretroviral therapy for HIV.
• Chemo‑radiation or targeted therapy for cancers.
• ACE inhibitors or ARBs to slow CKD progression.

Erythropoiesis‑Stimulating Agents (ESAs)

• Agents: epoetin alfa, darbepoetin alfa.
• Indications: CKD‑related anemia (Hb < 10 g/dL), chemotherapy‑induced ACD, or symptomatic anemia refractory to disease control.
• Target Hb: 10–11.5 g/dL (higher targets linked to increased thromboembolic risk).
• Monitor for hypertension, thromboembolic events, and iron status.

Iron Supplementation

Even when ferritin is normal, functional iron deficiency may exist. Intravenous (IV) iron is preferred over oral because hepcidin blocks absorption. Common regimens include:

• Iron sucrose 200 mg IV weekly for 5 weeks, or
• Ferric carboxymaltose 1 g IV over 15 minutes (single dose).

IV iron should be given under supervision due to rare anaphylactic reactions.

Blood Transfusion

Reserved for life‑threatening anemia (Hb < 7 g/dL) or when rapid correction is essential (e.g., acute cardiac ischemia). Chronic transfusion carries risk of iron overload and alloimmunization, so it is not a long‑term solution.

Adjunctive Lifestyle Measures

• Balanced diet rich in protein, vitamin B12, folate, and vitamin C (enhances iron utilization).
• Regular moderate‑intensity aerobic activity (e.g., walking 30 minutes most days) to improve cardiovascular efficiency.
• Smoking cessation – smoking worsens chronic inflammation and impairs oxygen transport.

Living with Ineffective Erythropoiesis (Anemia of Chronic Disease)

Daily Management Tips

• Track symptoms in a journal—note fatigue level, shortness of breath, and any new chest discomfort.
• Take medications exactly as prescribed, especially ESAs and IV iron infusions.
• Stay hydrated—dehydration can falsely elevate hemoglobin concentration.
• Schedule regular labs every 1‑3 months (CBC, iron studies, creatinine) to monitor trends.
• Plan activity wisely—pace yourself, incorporate rest breaks, and use a ‘talk test’ to gauge exertion.
• Vaccinations—keep up with flu, pneumococcal, and hepatitis B vaccines to reduce infection‑related inflammation.
• Psychological support—living with chronic disease can cause depression; consider counseling or support groups.

When to Contact Your Healthcare Provider

• Hb drops by > 1 g/dL within a month without an obvious cause.
• New or worsening chest pain, palpitations, or syncope.
• Persistent shortness of breath at rest.
• Side‑effects from ESA therapy (e.g., high blood pressure).

Prevention

Because ACD is secondary to another disease, prevention focuses on minimizing chronic inflammation and protecting organ function.

• Optimal management of rheumatologic, renal, or infectious diseases per current guidelines.
• Maintain a healthy weight and engage in regular physical activity to reduce systemic inflammation.
• Avoid excessive alcohol and smoking, both of which exacerbate inflammatory pathways.
• Screen for and treat iron deficiency early to prevent compounding anemia.
• Vaccinate against infections that could trigger chronic inflammatory states.

Complications

If untreated or poorly managed, ACD can lead to:

• Cardiovascular strain – chronic low‑grade anemia forces the heart to work harder, increasing risk of left‑ventricular hypertrophy, heart failure, and myocardial infarction.
• Reduced quality of life – persistent fatigue limits independence and may cause depression.
• Impaired wound healing – oxygen delivery is critical for tissue repair.
• Exacerbation of the underlying disease – anemia can worsen renal function, reduce immune competence, and limit tolerance to chemotherapy.
• Increased mortality – large registry studies link moderate‑to‑severe ACD with higher all‑cause mortality in CKD and cancer patients (NIH, 2022).

When to Seek Emergency Care

---

References:
1. Mayo Clinic. “Anemia of chronic disease.” https://www.mayoclinic.org (accessed June 2026).
2. CDC. “Anemia.” https://www.cdc.gov (2024).
3. National Institutes of Health. “Kidney Disease and Anemia.” https://www.niddk.nih.gov (2022).
4. WHO. “Worldwide prevalence of anemia 2021.” https://www.who.int.
5. Cleveland Clinic. “Erythropoietin stimulating agents.” https://my.clevelandclinic.org (2023).
6. American Heart Association. “When to call emergency services for cardiac symptoms.” https://www.heart.org (2024).

```